IDEAYA Biosciences, Inc. $IDYA Stake Lifted by SG Americas Securities LLC

SG Americas Securities LLC boosted its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 169.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 54,137 shares of the company’s stock after buying an additional 34,020 shares during the period. SG Americas Securities LLC owned 0.06% of IDEAYA Biosciences worth $1,473,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of IDYA. Elevation Point Wealth Partners LLC acquired a new stake in shares of IDEAYA Biosciences in the 2nd quarter worth about $61,000. CWM LLC grew its position in IDEAYA Biosciences by 33.0% in the 2nd quarter. CWM LLC now owns 3,153 shares of the company’s stock worth $66,000 after purchasing an additional 782 shares during the last quarter. Daiwa Securities Group Inc. increased its stake in shares of IDEAYA Biosciences by 16.1% in the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after purchasing an additional 436 shares during the period. Parallel Advisors LLC raised its holdings in shares of IDEAYA Biosciences by 72.4% during the second quarter. Parallel Advisors LLC now owns 3,260 shares of the company’s stock valued at $69,000 after buying an additional 1,369 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in shares of IDEAYA Biosciences by 39.1% during the second quarter. PNC Financial Services Group Inc. now owns 3,344 shares of the company’s stock worth $70,000 after buying an additional 940 shares during the period. Institutional investors and hedge funds own 98.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on IDYA shares. Wall Street Zen upgraded IDEAYA Biosciences from a “hold” rating to a “buy” rating in a research report on Sunday, November 9th. Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Wednesday, October 8th. New Street Research set a $30.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, October 21st. JPMorgan Chase & Co. raised their target price on shares of IDEAYA Biosciences from $74.00 to $79.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Finally, BTIG Research reaffirmed a “buy” rating and issued a $62.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. Fifteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, IDEAYA Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $46.33.

IDEAYA Biosciences Price Performance

NASDAQ IDYA opened at $35.84 on Friday. The company has a market capitalization of $3.14 billion, a P/E ratio of -19.27 and a beta of 0.05. IDEAYA Biosciences, Inc. has a 12 month low of $13.45 and a 12 month high of $39.28. The company’s 50 day simple moving average is $34.59 and its 200 day simple moving average is $28.74.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, November 4th. The company reported $1.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $1.45. The company had revenue of $207.83 million for the quarter, compared to analyst estimates of $59.98 million. On average, analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.